ATPase

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1478 Oligomycin A <1 mg/mL 10 mg/mL <1 mg/mL
S7046 Brefeldin A <1 mg/mL 4 mg/mL <1 mg/mL
S7099 (-)-Blebbistatin <1 mg/mL 58 mg/mL <1 mg/mL
S2000 Sodium orthovanadate 36 mg/mL <1 mg/mL <1 mg/mL
S5454 Saikosaponin D <1 mg/mL 100 mg/mL <1 mg/mL
S2528 Ciclopirox <1 mg/mL 42 mg/mL 42 mg/mL
S3019 Ciclopirox ethanolamine <1 mg/mL 6 mg/mL 30 mg/mL
S2233 Esomeprazole sodium 73 mg/mL 73 mg/mL 73 mg/mL
S7266 Golgicide A <1 mg/mL 57 mg/mL 4 mg/mL
S2222 PF-3716556 <1 mg/mL 79 mg/mL 79 mg/mL
S7460 BTB06584 <1 mg/mL 84 mg/mL <1 mg/mL
S3699 2,3-Butanedione-2-monoxime 20 mg/mL 20 mg/mL 20 mg/mL
S8101 CB-5083 <1 mg/mL 82 mg/mL 13 mg/mL
S3628 BHQ <1 mg/mL 10 mg/mL 40 mg/mL
S8276 FCCP <1 mg/mL 50 mg/mL 50 mg/mL
S2623 Omecamtiv mecarbil (CK-1827452) <1 mg/mL 80 mg/mL 6 mg/mL
Catalog No. Information Product Use Citations Product Validations
S1478New

Oligomycin A

Oligomycin A is an inhibitor of ATP synthase, inhibits oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria.

S7046

Brefeldin A

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

S7099

(-)-Blebbistatin

(-)-Blebbistatin is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM in cell-free assays, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly.

S2000

Sodium orthovanadate

Sodium orthovanadate is an alkaline phosphatase and (Na,K)-ATPase inhibitor with IC50 of 10 μM.

S5554New

Lanatoside C

Lanatoside C, a cardiac glycoside which belongs to a class of compounds derived from plants called foxglove, possesses the ability to inhibit the interchange of Na+ and K+ across cell membrane and is widely used to treat anti-arrhythmias and heart failure.

S5454New

Saikosaponin D

Saikosaponin D, a calcium mobilizing agent (SERCA inhibitor), is a type of Saponin derivative, which is a component extracted from Bupleurum falactum. Saikosaponin D has anti-cancer activities.

S2528

Ciclopirox

Ciclopirox is a broad-spectrum antifungal agent working as an iron chelator.

S3019

Ciclopirox ethanolamine

Ciclopirox ethanolamine (Ciclopirox olamine, HOE 296) is a broad-spectrum antifungal agent working as an iron chelator.

S2233

Esomeprazole sodium

Esomeprazole Sodium is a sodium salt of esomeprazole that is a potent proton pump inhibitor with an IC50 of 0.076 mg/kg.

S7266

Golgicide A

Golgicide A is a potent and rapidly reversible GBF1 inhibitor.

S2222

PF-3716556

PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.

S7460

BTB06584

BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase.

S3699

2,3-Butanedione-2-monoxime

2,3-Butanedione monoxime (BDM) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II and inhibits skeletal and cardiac muscle contraction.

S8101

CB-5083

CB-5083 is a potent, selective, and orally bioavailable p97 AAA ATPase inhibitor with IC50 of 11 nM. Phase 1.

S3628

BHQ

BHQ is a potent and selective inhibitor of the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).

S8276

FCCP

FCCP is a potent uncoupler of oxidative phosphorylation in mitochondria that disrupts ATP synthesis by transporting protons across cell membranes.

S2623

Omecamtiv mecarbil (CK-1827452)

Omecamtiv mecarbil (CK-1827452) is a specific cardiac myosin activator and a clinical drug for left ventricular systolic heart failure. Phase 2.

Tags: ATPase inhibition | ATPase pump | ATPase activity | ATPase assay | sodium potassium ATPase pump | Na K-ATPase pump | Na K-ATPase activity | mitochondrial ATPase | Ca-ATPase pump | Na K-ATPase inhibition | myosin ATPase activity | H-ATPase pump | ATPase phosphorylation | ATPase assay protocol | HK-ATPase pump | Ca-ATPase activity | V-ATPase pump | sodium potassium ATPase activity | actomyosin ATPase activity | P-type ATPase pump